Reuters logo
Biotech Regeneron's profit jumps 37 pct on higher Eylea sales
2017年5月4日 / 上午10点36分 / 5 个月前

Biotech Regeneron's profit jumps 37 pct on higher Eylea sales

May 4 (Reuters) - Regeneron Pharmaceuticals Inc reported a 37.2 percent increase in first-quarter profit, driven by higher demand for its flagship eye drug Eylea.

The company said net income rose to $248.9 million, or $2.16 per share, in the quarter ended March 31, from $181.4 million, or $1.59 per share, a year earlier.

Total revenue, which also includes collaboration revenue from partners Sanofi SA and Bayer AG, rose nearly 10 percent to $1.32 billion.

U.S. sales of Eylea rose 9 percent in the latest quarter.

Eylea accounted for about 68 percent of the U.S. biotechnology company’s total revenue in 2016. (Reporting by Divya Grover in Bengaluru; Editing by Savio D‘Souza)

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below